Tyra Biosciences Reports Q4/FY25 Results, Extends Cash Runway to 2027, Details 'Dabogratinib 3x3' Strategy

summarizeSummary

Tyra Biosciences reported Q4 and full-year 2025 financial results, confirming a cash runway through at least 2027 and detailing a focused 'dabogratinib 3x3' clinical strategy with key Phase 2 data readouts expected in 2026.

check_boxKey Events

• Extended Cash Runway

  The company reported $256.0 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which is expected to fund operations through at least 2027.

• Strategic Pipeline Focus

  Tyra Biosciences launched its 'dabogratinib 3x3' strategy, prioritizing three late-stage clinical studies in LG-UTUC, IR NMIBC, and ACH, and exiting metastatic bladder cancer to optimize capital allocation.

• Upcoming Clinical Milestones

  Interim Phase 2 data readouts are on track for SURF302 by the end of 1H 2026 and for BEACH301 in 2H 2026. The first patient in the SURF303 study is anticipated to be dosed in 2026.

• Leadership Team Strengthened

  In Q4 2025, the company appointed Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer to support the advancement of dabogratinib.

auto_awesomeAnalysis

This 8-K provides the detailed financial and operational context for Tyra Biosciences' annual results. The reported cash, cash equivalents, and marketable securities of $256.0 million, extending the cash runway through at least 2027, significantly de-risks the company's near-term financial position, which is crucial for a clinical-stage biotechnology company. The clear articulation of the 'dabogratinib 3x3' strategy, focusing resources on high-potential indications and exiting metastatic bladder cancer, demonstrates a disciplined approach to pipeline development. Investors should closely monitor the upcoming Phase 2 data readouts for SURF302 and BEACH301, as these will be key catalysts for the stock.